Skip to main content

Entinostat + Nivolumab Yields Durable Results in Some Pancreatic Cancer Patients

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 22, 2024.

By Elana Gotkine HealthDay Reporter

FRIDAY, Nov. 22, 2024 -- Combination treatment with entinostat and nivolumab results in durable responses in a small subset of patients with advanced pancreatic ductal adenocarcinoma (PDA), according to a study published online Nov. 12 in Nature Communications.

Marina Baretti, M.D., from the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore, and colleagues combined entinostat and nivolumab in patients with advanced PDA in a phase 2 study. A 14-day lead-in of entinostat 5 mg orally once weekly was followed by entinostat and nivolumab treatment.

Twenty-seven evaluable patients were enrolled between November 2017 and November 2020. The researchers found partial responses in three patients (objective response rate, 11 percent), with a median response duration of 10.2 months. Median progression-free survival was 1.89 months and overall survival was 2.729 months. Nineteen patients (63 percent) had grade ≥3 treatment-related adverse events, including reduced lymphocyte count, anemia, hypoalbuminemia, and hyponatremia. Entinostat yielded increases in dendritic cell activation and maturation. In a small subset of PDA patients, entinostat and nivolumab showed durable responses, although the primary end point was not met.

"This study creates a roadmap for this strategy, and future areas of exploration include additional mechanistic studies that will lead to combinatorial approaches, both preclinically and clinically, to expand the subset of patients that could benefit from an histone deacetylase inhibitor-based immunomodulatory strategy," the authors write.

Several authors disclosed ties to biopharmaceutical companies, including Syndax, which manufactures entinostat and supplied the study medications.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

2000 to 2021 Saw Increase in Incidence of Pancreatic Adenocarcinoma

WEDNESDAY, April 23, 2025 -- From 2000 to 2021, there was an increase in the incidence of pancreatic adenocarcinoma, which was seen in all age groups, according to a study...

Disparities Evident in Treatment, Survival for Patients With Pancreatic Cancer

THURSDAY, April 17, 2025 -- Among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC), racial and ethnic minority patients and socially vulnerable populations are...

Nanosensor Assay Promising for Pancreatic Cancer Detection

FRIDAY, Feb. 28, 2025 -- A rapid nanosensor assay that measures serum protease cleavage of a target-probe nanosensor can identify pancreatic ductal adenocarcinoma (PDAC) samples...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.